A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 685 participants.
Also called NCT01217073
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 685 participants
- Sponsor
- Registry
-
NCT01217073 -
2010-022193-13 -
2011-000656-42
-
- Main results
- Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01217073. Randomized; triple masking; primary purpose treatment. Start 2010-10-08 (actual); primary completion 2012-01-03 (actual). Results posted on 2015-10-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Omarigliptin
- Intervention (Drug)
- Placebo to omarigliptin
- Intervention (Drug)
- Pioglitazone
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Placebo to metformin
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01217073- Content hash
cd87ac84e84d4353d798017b1813ff3c88e089488ea888d9cd5fb8fb37041ddb